Cargando…
Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36
Autor principal: | Shore, Neal D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676143/ https://www.ncbi.nlm.nih.gov/pubmed/36420113 http://dx.doi.org/10.1016/j.euros.2022.10.018 |
Ejemplares similares
-
Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice
por: Gómez Rivas, Juan, et al.
Publicado: (2022) -
Techniques to find new physics, according to Francesco Riva
por: ATLAS Collaboration
Publicado: (2015) -
Albert Victor Neale
Publicado: (1970) -
Giorgio Strehler /
por: Battistini, Fabio
Publicado: (1980) -
Giorgio Bellettini
Publicado: (1964)